文献速递胸部肿瘤头颈与中枢神经肿瘤

塞普替尼治疗RET融合阳性非小细胞肺癌患者的中枢神经系统疾病

Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib.
PubMed 文献 · J Thorac Oncol · 2023-01-16

研究纳入61例RET融合阳性晚期非小细胞肺癌患者,接受塞普替尼治疗,评估中枢神经系统转移的累积发生率。基线无中枢神经系统疾病患者36个月内中枢神经系统进展累积发生率为0%,基线有中枢神经系统疾病患者36个月时为20%。早期启动塞普替尼与中枢神经系统转移形成和进展率降低相关,可能起预防作用。

要点

  • 基线无中枢神经系统疾病的患者接受塞普替尼治疗期间未观察到中枢神经系统进展。
  • 基线有中枢神经系统疾病的患者中,塞普替尼治疗期间中枢神经系统进展罕见。
  • 早期启动塞普替尼与中枢神经系统转移形成和进展率降低相关,可能起预防作用。

核心结论

  • 基线无中枢神经系统疾病的患者接受塞普替尼治疗未观察到中枢神经系统进展。
  • 基线有中枢神经系统疾病的患者中,塞普替尼治疗期间中枢神经系统进展罕见。
  • 早期启动塞普替尼与中枢神经系统转移形成和进展率降低相关,可能起预防作用。

研究设计与样本

  • 研究纳入61例RET融合阳性晚期非小细胞肺癌患者,来自LIBRETTO-001试验(NCT03157128)或LIBRETTO-201扩展准入项目(NCT03906331),接受塞普替尼治疗,伴或不伴中枢神经系统转移。
  • 中枢神经系统转移的累积发生率作为感兴趣事件评估,系统性疾病进展和死亡视为竞争风险。

主要发现

  • 中位年龄65岁,最常见的5'融合伴侣为KIF5B(67%)和CCDC6(18%)。
  • 24例(39%)接受过含铂化疗,20例(33%)接受过多激酶抑制剂治疗。
  • 塞普替尼中位治疗时间21.8个月。
  • 30例(49%)基线有中枢神经系统疾病,31例(51%)基线无中枢神经系统疾病。
  • 基线有中枢神经系统疾病患者中枢神经系统进展累积发生率在6、12、18、24和36个月分别为3%(95%CI:0%-10%)、10%(95%CI:0%-22%)、17%(3%-30%)、17%(3%-30%)和20%(5%-35%)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Central nervous system (CNS) metastases develop in nearly half of patients with RET fusion-positive NSCLCs and cause morbidity and mortality. The selective RET inhibitor selpercatinib treats existing intracranial disease, but no studies have investigated whether early initiation of selpercatinib is associated with decreased development of CNS metastases. METHODS: A total of 61 patients with RET fusion-positive advanced NSCLC with and without CNS metastases treated with selpercatinib on the LIBRETTO-001 trial (NCT03157128) or the LIBRETTO-201 expanded access program (NCT03906331) were identified. Cumulative incidence rates (CIRs) for CNS metastases were assessed as an event of interest; systemic progression of disease and death were considered competing risks. RESULTS: The median age was 65 years, and the most common 5' fusion partners were KIF5B (67%) and CCDC6 (18%). There were 24 patients (39%) who received prior platinum chemotherapy and 20 patients (33%) who received prior multikinase inhibition. The median time on selpercatinib was 21.8 months. Furthermore, 30 patients (49%) had CNS disease at baseline and 31 patients (51%) had no baseline CNS disease. CIRs of CNS progression among patients with baseline CNS disease were 3% (95% confidence interval [CI]: 0%-10%), 10% (95% CI: 0%-22%), 17% (3%-30%), 17% (3%-30%), and 20% (5%-35%) at 6, 12, 18, 24, and 36 months, respectively. CIR for CNS progression among patients without baseline CNS disease was 0% at 6, 12, 18, 24, and 36 months (95% CI: 0%-0%). CONCLUSIONS: CNS progression was not observed with selpercatinib therapy in patients without baseline CNS disease. CNS progression on selpercatinib was rare in patients with baseline CNS disease. Early initiation of selpercatinib is associated with decreased rates of CNS metastasis formation and progression and may play a preventive role.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Murciano-Goroff YR, Falcon CJ, Lin ST, et al. Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib. J Thorac Oncol. 2023. PMID: 36657661. doi:10.1016/j.jtho.2023.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。